Reform of the Morbi-RSA will be consistently continued
12.04.2021 13:20
“With the planned Health Care Development Act (GVWG), politicians are consistently continuing the reform of the financial equalization of health insurance companies, Morbi-RSA. This means that further open construction sites at Morbi-RSA will be closed, said Ulrike Elsner, CEO of the Association of Replacement Funds. V. (vdek), on the occasion of the hearing on the law in the German Bundestag on April 12, 2021.
The collective law contains sensible RSA adjustments to allocations for child sickness benefit and for those insured abroad. Politicians are thus continuing to work towards creating fair competitive conditions between health insurance companies. However, “important,” says Elsner, is that these two regulations should be brought forward in time.
Actual cost compensation for child sickness benefit for the compensation year 2021!
On the one hand, this applies to child sickness benefit, for which the new compensation mechanism - taking into account the actual actual costs of the health insurance companies - should apply from the compensation year 2021 instead of only in 2023. The health insurance companies could then also be assigned the expansion of child sickness benefits - decided as a result of the corona pandemic - based on their respective level of concern via the Morbi-RSA. Overall, an actual cost compensation for child sickness benefit is appropriate, as health insurance companies cannot influence the amount of costs through control activities.
Implement regulations for those insured abroad as early as the 2022 compensation year
On the other hand, the reform should be brought forward for the RSA regulations for insured persons living abroad. According to the cabinet decision, the country-specific costs should be determined from 2023. Here too, timely implementation – technically possible from 2022 – is advisable. Overall, the country-specific view enables a more precise consideration of the costs incurred, says Elsner. The background to this regulation is that, due to different cost levels in the individual countries, there are currently different service expenditures from health insurance companies for the same treatment of insured persons living abroad. These cost differences have not yet been adequately taken into account in Morbi-RSA.